SCHEMBL557899

SCHEMBL557899

[c]1nccc(-c2ccccc2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
RAB9A P51151 3/20 0.41
MEN1 O00255 2/20 0.41
ADORA2A P29274 2/20 0.41
AURKA O14965 1/20 0.41
HSP90AA1 P07900 1/20 0.41
PRKACA P17612 1/20 0.41
NOTUM Q6P988 1/20 0.37
ASIC3 Q9UHC3 2/20 0.36
ALDH1A1 P00352 3/20 0.35
ADORA1 P30542 1/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NISCH Q9Y2I1 2/20 0.34
IDO1 P14902 1/20 0.34
METAP2 P50579 1/20 0.34
KEAP1 Q14145 1/20 0.34
MTOR P42345 1/20 0.34
ADK P55263 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL989535 0.79 CYP2A6 (0.52) RAB9AHSP90AA1ALDH1A1HPGDSMN1; SMN2
SCHEMBL3597375 0.78 RAB9A (0.41) KMT2ARAB9AMEN1ALDH1A1L3MBTL1
SCHEMBL16720064 0.77 KMO (0.45) KMT2AMEN1PRKACANOTUMALDH1A1
SCHEMBL3654046 0.77 CYP1A2 (0.47) KMT2ARAB9AMEN1ALDH1A1HPGD
SCHEMBL15477525 0.77 KMO (0.45) RAB9ANOTUMSMN1; SMN2IDO1NPC1
SCHEMBL11107619 0.77 METAP2 (0.45) METAP2KEAP1
SCHEMBL16720101 0.77 HSD17B1 (0.52) METAP2
SCHEMBL2909003 0.75 MEN1 (0.52) KMT2ARAB9AMEN1ADORA2AALDH1A1
SCHEMBL558888 0.74 KDM4E (0.58) RAB9AHSP90AA1ALDH1A1HPGDSMN1; SMN2
SCHEMBL990825 0.74 CYP2A6 (0.39) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118290273-A Fluorenyl deuterated amino compound and organic light-emitting device 南京高光半导体材料有限公司 2024-07-05 CN claimed
CN-118184522-A Amino compound with deuterated fluorenyl and organic light-emitting device 南京高光半导体材料有限公司 2024-06-14 CN claimed
WO-2024119977-A1 ORGANIC COMPOUND AND ORGANIC LIGHT EMISSION DIODE DEVICE COMPRISING SAME 四川阿格瑞新材料有限公司 2024-06-13 WO claimed
US-11987588-B2 Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2024-05-21 US claimed
CN-117964501-A Spirobifluorenylamino compound and organic electroluminescent device 南京高光半导体材料有限公司 2024-05-03 CN claimed
CN-117964500-A Amino compound with spirobifluorene group and organic electroluminescent device 南京高光半导体材料有限公司 2024-05-03 CN claimed
CN-117946044-A Amino compound with benzophenanthrene furan group and organic light-emitting device 南京高光半导体材料有限公司 2024-04-30 CN claimed
CN-117720584-A Cyclometallated iridium (III) complex, preparation method and application thereof as photosensitizer 中国科学院深圳先进技术研究院 2024-03-19 CN claimed
CN-117682998-A Electron transport material, preparation method thereof and light-emitting device 吉林奥来德光电材料股份有限公司 2024-03-12 CN claimed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
WO-1999025789-A1 LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL SHUTTER THE SECRETARY OF STATE FOR DEFENCE (GB) 1999-05-27 WO claimed
EP-0903391-A1 \"Liquid crystal composition and liquid crystal shutter\ Sharp Kabushiki Kaisha (JP) 1999-03-24 EP claimed
WO-1998047880-A1 ISOXAZOLE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1998-10-29 WO claimed
WO-1998008813-A1 COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED PYRROLIDINE LIBRARIES ELI LILLY AND COMPANY (US) 1998-03-05 WO claimed
EP-0821670-A1 N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS Novartis AG (CH) 1998-02-04 EP claimed
US-5654326-A SEPTIC SHOCK; HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE ELI LILLY AND COMPANY (US) 1997-08-05 US claimed
US-5641800-A ALLEVIATE EFFECT OF SEPTIC SHOCK, ADULT RESPIRATORY DISTRESS SYNDROME, PANCREATITIS, TRAUMA, BRONCHIAL ASTHMA, ALLERGIC RHINITIS, AND RHEUMATOID ARTHRITIS ELI LILLY AND COMPANY (US) 1997-06-24 US claimed
WO-1996033170-A1 N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS NOVARITS AG (CH) 1996-10-24 WO claimed
US-4659736-A Benzoyl urea compounds as agents for repelling snails and slugs BAYER AKTIENGESELLSCHAFT (DE) 1987-04-21 US claimed
EP-0150031-A2 Agent for combatting slugs and snails BAYER AG (DE) 1985-07-31 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11987588-B2 Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto ADRB3, ADRB1, ADRB2 KMT2A 4684/4885RAB9A 2400/4885MEN1 4306/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR KMT2A 4282/4885RAB9A 1472/4885MEN1 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.